13958-93-5

Basic information

• Product Name: 3,5-DICHLOROISONICOTINIC ACID
• Synonyms: 3,5-Dichloropyridine-4-carboxylic acid 98%;3,5-DICHLOROPYRIDINE-4-CARBOXYLIC ACID;3,5-DICHLOROISONICOTINIC ACID;3,5-Dichloroisonicotinic acid(3,5-Dichloropyridine-4-carboxylic acid);3,5-DICHLORO-4-PYRIDINECARBOXYLIC ACID;TIMTEC-BB SBB003624;RARECHEM AL BE 0919;dichloroisonicotinicacid
• CAS NO: 13958-93-5
• Molecular Formula: C₆H₃Cl₂NO₂
• Molecular Weight: 192
• Product Categories: Building Blocks;C5 to C6;C6 to C7;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyridines;Chloropyridines;Halopyridines
• Mol File: 13958-93-5.mol
• Article Data: 16

Chemical Properties

• Melting Point: 230 °C (dec.)(lit.)
• Boiling Point: 383.003 °C at 760 mmHg
• Flash Point: 185.434 °C
• Appearance: /
• Density: 1.612 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.16±0.25(Predicted)
• CAS DataBase Reference: 3,5-DICHLOROISONICOTINIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DICHLOROISONICOTINIC ACID(13958-93-5)
• EPA Substance Registry System: 3,5-DICHLOROISONICOTINIC ACID(13958-93-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 13958-93-5(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 32, p. 2178, 1989 DOI: 10.1021/jm00129a026

InChI:InChI=1/C6H3Cl2NO2/c7-3-1-9-2-4(8)5(3)6(10)11/h1-2H,(H,10,11)

Upstream product

• 124-38-9 carbon dioxide 
• 2457-47-8 3,5-dichloropyridine 
• 75-09-2 dichloromethane 
• 55-22-1 pyridine-4-carboxylic acid 
• 7719-09-7 thionyl chloride 
• 42935-09-1 tetrachloro-isonicotinoyl chloride 

Downstream Products

• 70593-51-0 3,5-dichloro-4-pyridine-carboxamide 
• 1253799-61-9 3-(benzyloxy)-5-chloroisonicotinic acid 
• 254760-48-0 3,5-dichloro-N-(4-formyl-phenyl)-isonicotinamide 
• 405230-58-2 N-(4-{[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-phenyl)-3,5-dichloro-isonicotinamide 
• 405058-84-6 3,5-Dichloro-N-[4-(2-oxo-ethyl)-benzyl]-isonicotinamide 
• 1239321-48-2 (R)-3,5-dichloro-N-((2-methyl-2-azabicyclo[2.2.2]octan-1-yl)(phenyl)methyl)isonicotinamide 
• 1254367-47-9 methyl 3-(benzyloxy)-5-chloroisonicotinate 
• 773136-79-1 3,5-dichloroisonicotinic acid ethyl ester 
• 856931-63-0 C₂₉H₂₉Cl₃F₃N₃O₂ 
• 1304776-48-4 C₂₉H₂₉Cl₃F₃N₃O₂ 
• 856931-68-5 C₃₀H₂₉Cl₂F₃N₄O₂ 
• 1304776-47-3 C₃₀H₂₉Cl₂F₃N₄O₂ 
• 856931-60-7 C₂₉H₃₀Cl₂F₃N₃O₂ 

Relevant articles and documents

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

PHENYLALANINE ENAMIDE DERIVATIVES CONTAINING A SPIRO`3.5!NON-1-ENE RING FOR USE AS INTEGRIN INHIBITORS

Phenylalanine enamide derivatives of formula (1) are described: wherein R1 is a -CH3, -(CH2)3CH3, -CH2CH20H, -CH2CH20CH3, -CH2CH2

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides

The unsymmetrical nicotinamide-N-oxide moiety in compound 1 was replaced with symmetrical isonicotinamides as well as 4,6-dimethyl pyrimidine-5-carboxamides. Compound 16 from the latter set reduced the number of rotamers, improved potency of inhibiting UIV entry, slightly diminished the affinity for the muscarine receptors and showed very good oral absorption.